SR 57227A is a partial agonist/partial antagonist of 5-HT 3 receptor and inhibits subsequent 5-HT- or SR 57227A-induced 5-HT 3 receptor current

Yukiko Nakamura, Makoto Kondo, Yoshihisa Koyama, Shoichi Shimada

Biochem Biophys Res Commun. 2019 Jan 8;508(2):590-596.

PMID: 30509492

Abstract:

The serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptors are transmembrane ligand-gated ion channels. Although several 5-HT3 receptor agonists have been used as preclinical tools, SR 57227A is the most commonly used 5-HT3 receptor agonist with the ability to cross the blood brain barrier. However, the precise pharmacological profile of SR 57227A remains unclear. Therefore, we examined the pharmacological profile of SR 57227A at the 5-HT3A and 5-HT3AB receptors. We microinjected Xenopus laevis oocytes with human 5-HT3A complementary RNA (cRNA) or a combination of human 5-HT3A and human 5-HT3AB cRNA and performed two electrode voltage clamp recordings of 5-HT3A and 5-HT3AB receptor current in the presence of SR 57227A. Results showed that SR 57227A acts as partial agonist/partial antagonist at the 5-HT3 receptor. Interestingly, SR 57227A specifically reduced subsequent current amplitudes induced by 5-HT or SR 57227A. Based on its 5-HT3 receptor partial agonist/partial antagonist properties, we predict that SR 57227A functions as a serotonin stabilizer.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP77145610	SR 57227A		77145-61-0	Price
AP10397521	3,3′,5,5′-Tetracarboxydiphenylmethane		10397-52-1	Price